Literature DB >> 16428767

Tumor necrosis factor alpha and gamma interferon, but not hemorrhage or pathogen burden, dictate levels of protective fibrin deposition during infection.

Isis K Mullarky1, Frank M Szaba, Kiera N Berggren, Lawrence W Kummer, Lindsey B Wilhelm, Michelle A Parent, Lawrence L Johnson, Stephen T Smiley.   

Abstract

While coagulation often causes pathology during infectious disease, we recently demonstrated that fibrin, a product of the coagulation pathway, performs a critical protective function during acute toxoplasmosis (L. L. Johnson, K. N. Berggren, F. M. Szaba, W. Chen, and S. T. Smiley, J. Exp. Med. 197:801-806, 2003). Here, we investigate the mechanisms regulating the formation of this protective fibrin. Through comparisons of Toxoplasma-infected wild-type and cytokine-deficient mice we dissociate, for the first time, the relative fibrin-regulating capacities of pathogen products, host cytokines, and infection-stimulated hemorrhage. Remarkably, neither the pathogen burden nor hemorrhage is a primary regulator of fibrin levels. Rather, two type 1 cytokines exert dominant and counterregulatory roles: tumor necrosis factor alpha (TNF-alpha), acting via the type 1 TNF-alpha receptor, promotes fibrin deposition, while gamma interferon (IFN-gamma), acting via STAT1 and IFN-gamma receptors expressed on radioresistant cells, suppresses fibrin deposition. These findings have important clinical implications, as they establish that cytokines known to regulate pathological coagulation also dictate levels of protective fibrin deposition. We present a novel model depicting mechanisms by which the immune system can destroy infected tissue while independently restraining hemorrhage and promoting tissue repair through the deliberate deposition of protective fibrin.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16428767      PMCID: PMC1360344          DOI: 10.1128/IAI.74.2.1181-1188.2006

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  57 in total

Review 1.  Role of fibrin deposition in the pathogenesis of intraabdominal infection.

Authors:  O D Rotstein
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-11       Impact factor: 3.267

2.  Tumor necrosis factor-alpha induces activation of coagulation and fibrinolysis in baboons through an exclusive effect on the p55 receptor.

Authors:  T van der Poll; P M Jansen; K J Van Zee; M B Welborn; I de Jong; C E Hack; H Loetscher; W Lesslauer; S F Lowry; L L Moldawer
Journal:  Blood       Date:  1996-08-01       Impact factor: 22.113

3.  IFN-gamma inhibits thrombin- and endotoxin-induced plasminogen activator inhibitor type 1 in human endothelial cells.

Authors:  M Gallicchio; P Hufnagl; J Wojta; P Tipping
Journal:  J Immunol       Date:  1996-09-15       Impact factor: 5.422

4.  Administration of gamma interferon in human subjects decreases plasminogen activation and fibrinolysis without influencing C1 inhibitor.

Authors:  P Gluszko; A Undas; S Amenta; A Szczeklik; A H Schmaier
Journal:  J Lab Clin Med       Date:  1994-02

Review 5.  New treatment strategies for disseminated intravascular coagulation based on current understanding of the pathophysiology.

Authors:  Marcel Levi; Evert de Jonge; Tom van der Poll
Journal:  Ann Med       Date:  2004       Impact factor: 4.709

6.  Differential effects of anti-tumor necrosis factor monoclonal antibodies on systemic inflammatory responses in experimental endotoxemia in chimpanzees.

Authors:  T van der Poll; M Levi; S J van Deventer; H ten Cate; B L Haagmans; B J Biemond; H R Büller; C E Hack; J W ten Cate
Journal:  Blood       Date:  1994-01-15       Impact factor: 22.113

7.  Parasite-induced IL-12 stimulates early IFN-gamma synthesis and resistance during acute infection with Toxoplasma gondii.

Authors:  R T Gazzinelli; M Wysocka; S Hayashi; E Y Denkers; S Hieny; P Caspar; G Trinchieri; A Sher
Journal:  J Immunol       Date:  1994-09-15       Impact factor: 5.422

8.  Th1 and Th2 T-helper cells exert opposite regulatory effects on procoagulant activity and tissue factor production by human monocytes.

Authors:  G Del Prete; M De Carli; R M Lammel; M M D'Elios; K C Daniel; B Giusti; R Abbate; S Romagnani
Journal:  Blood       Date:  1995-07-01       Impact factor: 22.113

9.  Expression of murine CD38 defines a population of long-term reconstituting hematopoietic stem cells.

Authors:  T D Randall; F E Lund; M C Howard; I L Weissman
Journal:  Blood       Date:  1996-05-15       Impact factor: 22.113

10.  Association of CD4+ T cell-dependent, interferon-gamma-mediated necrosis of the small intestine with genetic susceptibility of mice to peroral infection with Toxoplasma gondii.

Authors:  O Liesenfeld; J Kosek; J S Remington; Y Suzuki
Journal:  J Exp Med       Date:  1996-08-01       Impact factor: 14.307

View more
  5 in total

Review 1.  Therapeutic targeting of liver inflammation and fibrosis by nanomedicine.

Authors:  Matthias Bartneck; Klaudia Theresa Warzecha; Frank Tacke
Journal:  Hepatobiliary Surg Nutr       Date:  2014-12       Impact factor: 7.293

2.  In situ assays demonstrate that interferon-gamma suppresses infection-stimulated hepatic fibrin deposition by promoting fibrinolysis.

Authors:  I K Mullarky; F M Szaba; C G Winchel; M A Parent; L W Kummer; N Mackman; L L Johnson; S T Smiley
Journal:  J Thromb Haemost       Date:  2006-07       Impact factor: 5.824

3.  Granuloma encapsulation is a key factor for containing tuberculosis infection in minipigs.

Authors:  Olga Gil; Ivan Díaz; Cristina Vilaplana; Gustavo Tapia; Jorge Díaz; María Fort; Neus Cáceres; Sergio Pinto; Joan Caylà; Leigh Corner; Mariano Domingo; Pere-Joan Cardona
Journal:  PLoS One       Date:  2010-04-06       Impact factor: 3.240

Review 4.  Immune response and immunopathology during toxoplasmosis.

Authors:  Christopher D Dupont; David A Christian; Christopher A Hunter
Journal:  Semin Immunopathol       Date:  2012-09-07       Impact factor: 9.623

Review 5.  A spotlight on liquefaction: evidence from clinical settings and experimental models in tuberculosis.

Authors:  Pere-Joan Cardona
Journal:  Clin Dev Immunol       Date:  2011-03-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.